Compare KRRO & CVGI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KRRO | CVGI |
|---|---|---|
| Founded | 2014 | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Auto Parts:O.E.M. |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 187.9M | 167.7M |
| IPO Year | 2019 | 2004 |
| Metric | KRRO | CVGI |
|---|---|---|
| Price | $10.72 | $4.54 |
| Analyst Decision | Buy | |
| Analyst Count | 12 | 0 |
| Target Price | ★ $34.80 | N/A |
| AVG Volume (30 Days) | 191.8K | ★ 359.4K |
| Earning Date | 05-13-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 316.18 |
| EPS | N/A | ★ 0.04 |
| Revenue | $6,392,000.00 | ★ $755,231,000.00 |
| Revenue This Year | N/A | $4.84 |
| Revenue Next Year | N/A | $5.36 |
| P/E Ratio | ★ N/A | $115.50 |
| Revenue Growth | ★ 181.46 | 14.06 |
| 52 Week Low | $5.20 | $1.29 |
| 52 Week High | $55.89 | $5.88 |
| Indicator | KRRO | CVGI |
|---|---|---|
| Relative Strength Index (RSI) | 34.70 | 44.17 |
| Support Level | $9.76 | $4.32 |
| Resistance Level | $14.53 | $5.77 |
| Average True Range (ATR) | 0.98 | 0.29 |
| MACD | -0.37 | -0.01 |
| Stochastic Oscillator | 7.37 | 16.67 |
Korro Bio Inc is a biopharmaceutical company with a mission to discover, develop, and commercialize a new class of genetic medicines based on editing RNA, enabling the treatment of both rare and highly prevalent diseases. It is generating a portfolio of differentiated programs that are designed to harness the body's natural RNA editing process to effect a precise yet transient single base edit. By editing RNA instead of DNA, Korro Bio is expanding the reach of genetic medicines by delivering additional precision and tunability. The company operates and manages its business as one reportable segment and one operating segment, which is the business of discovering, developing and commercializing therapies derived from or incorporating its RNA-editing technology.
Commercial Vehicle Group Inc and its subsidiaries are a globalised provider of systems, assemblies, and components to international commercial vehicle markets and electric vehicle markets. It delivers real solutions to complex design, engineering, and manufacturing problems while creating positive change for customers, industries, and communities it serves. The company has its manufacturing operations in the United States, Mexico, China, the United Kingdom, the Czech Republic, Ukraine, Morocco, Thailand, India, and Australia. Organisations' products are mainly sold in North America, Europe, and the Asia-Pacific region. It has three segments: Global Seating Segment, Global Electrical systmem, and Trim Systems and Components Segment, with the majority of revenue from Global Seating Segment.